{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-071084","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.967270+00:00","generated_at":"2026-06-07T11:19:54.713221+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Crinetics reports positive initial Phase 2 data for paltusotine in carcinoid syndrome; 65% symptom reduction","bullets":["65% reduction in excess bowel movements and 65% reduction in flushing frequency in evaluable patients.","No treatment-related severe or serious adverse events; most AEs mild-to-moderate (diarrhea, headache, abdominal pain).","87% (13/15) of completers enrolled in long-term extension; study enrollment complete (N=36).","Topline results from full Phase 2 study expected in first half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-071084","json":"https://secwatch.observer/filing/0000950170-23-071084.json","markdown":"https://secwatch.observer/filing/0000950170-23-071084.md","text":"https://secwatch.observer/filing/0000950170-23-071084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023071084/0000950170-23-071084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023071084/crnx-20231218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:19:54.713221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}